About 18 results found for searched term "125-12-2" (0.123 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M18542 | Isobornyl acetate | Others |
| Isobornyl acetate | ||
| M10072 | AFN-1252 | Antibiotic |
| API-1252; Debio 1452 | ||
| AFN-1252 (API-1252; Debio-1452) is an enoyl-(acyl-carrier protein) reductase fabl inhibitor. AFN-1252 exhibits typical MIC90 values of ⩽0.015 μg/ml against diverse clinical isolates of S. aureus. | ||
| M10956 | PAT-1251 | Monoamine Oxidase |
| PAT-1251 is a potent, selective, orally lysanyl oxidase-like protein 2 (LOXL2) inhibitor of hLOXL2 and hLOXL3 IC50 The values were 0.71 and 1.17 μM, respectively, and the inhibition of LOXL2 in mice, rats, and dogs was strong.IC50 Values are 0.10, 0.12, and 0.16 μM, respectively; PAT-1251 can be used for studies of a variety of fibrous diseases. | ||
| M11249 | (+)-Enitociclib | CDK |
| (+)-BAY-1251152; (+)-VIP152 | ||
| (+) -enitociclib ((+) -bay-1251152) is an enantiomer of Bay-1251152 with optical rotation of (+). (+) -enitociclib is a potent selective CDK9 inhibitor with an IC50 of 3 nM. (+) -enitociclib has antitumor activity. | ||
| M11415 | (Rac)-JBJ-04-125-02 | EGFR/HER2 |
| JBJ-04-125-02 racemate | ||
| (Rac)-JBJ-04-125-02 is a racemate of JBJ-04-125-02, which is a potent, selectively mutated, allosteric and oral active EGFR inhibitor. The IC50 of EGFRL858R/T790M was 0.26 nM. | ||
| M13943 | NBI-74330 | CXCR |
| NBI-74330 is a potent antagonist for CXCR3, and exhibits potent inhibition of (125I)CXCL10 and (125I)CXCL11 specific binding with Ki of 1.5 and 3.2 nM, respectively. | ||
| M20606 | SAR125844 | c-Met |
| SAR125844 is a potent intravenously active and highly selective MET kinase inhibitor, displaying nanomolar activity against the wild-type kinase (IC50 value of 4.2 nmol/L) and H1094Y, Y1235D, M1250T, L1195V, and D1228H kinase domain mutants (IC50 values of 0.22, 1.7, 6.5, 65, and 81 nmol/L, respectively). | ||
| M21177 | (-)-Enitociclib | CDK |
| (-)-BAY-1251152; (-)-VIP152 | ||
| (-)-Enitociclib ((-)-BAY-1251152) is an enantiomer of BAY-1251152 with a (-) spin. BAY-1251152 is a potent and highly selective inhibitor of cell cycle-dependent protein kinase (PTEF/CDK9). | ||
| M25254 | Abagovomab | Others |
| Anti-Human CA-125 Recombinant Antibody | ||
| Abagovomab (Anti-Human CA-125 Recombinant Antibody) is a murine monoclonal anti-idiotypic antibody, against the tumor-associated antigen, CA-125. Abagovomab is generated by a mouse hybridoma, can imitate the human TAA, CA-125. Abagovomab can elicit humoral and cellular immune responses against ovarian cancer (oc). | ||
| M28110 | QTX125 | HDAC |
| QTX125 is a potent and highly selective HDAC6 inhibitor. QTX125 exhibits excellent selectivity over other HDACs. QTX125 has antitumor effects. | ||
| M28134 | Sampatrilat | ACE |
| UK-81252 | ||
| Sampatrilat (UK-81252) is a potent and orally active vasopeptidase inhibitor of ACE and neutral endopeptidase (NEP). Sampatrilat inhibits C-domain ACE (Ki=13.8 nM) 12.4-fold more potent than that for the N-domain (Ki=171.9 nM). Sampatrilat (UK-81252) can be used for the study of chronic heart failure and blood pressure regulation. | ||
| M28640 | MSN-125 | Bcl-2 |
| MSN-125 is a potent Bax and Bak oligomerization inhibitor. MSN-125 prevents mitochondrial outer membrane permeabilization (MOMP) with an IC50 of 4 μM. MSN-125 potently inhibits Bax/Bak-mediated apoptosis in HCT-116, BMK Cells, and primary cortical neurons, protects primary neurons against glutamate excitotoxicity. | ||
| M28667 | (±)-Enitociclib | CDK |
| (±)-BAY-1251152; (±)-VIP152 | ||
| (±)-Enitociclib ((±)-BAY-1251152) is a racemic mixture of BAY-1251152. BAY-1251152 is a potent and highly selective PTEF/CDK9 inhibitor. | ||
| M29117 | Laninamivir | Anti-infection |
| R 125489 | ||
| Laninamivir (R 125489) is a potent influenza neuraminidase (NA) inhibitor with IC50s of 0.90 nM, 1.83 nM and 3.12 nM for avian H12N5 NA (N5), pH1N1 N1 NA (p09N1) and A/RI/5+/1957 H2N2 N2 (p57N2), respectively. | ||
| M29151 | JBJ-04-125-02 | EGFR/HER2 |
| JBJ-04-125-02 is a potent, mutant-selective, allosteric and orally active EGFR inhibitor with an IC50 of 0.26 nM for EGFRL858R/T790M. JBJ-04-125-02 can inhibit cancer cell proliferation and EGFRL858R/T790M/C797S signaling. JBJ-04-125-02 has anti-tumor activities. | ||
| M29821 | HS-276 | IRAK |
| HS-276 is an orally active, potent and highly selective TAK1 inhibitor, with a Ki of 2.5 nM. HS-276 shows significant inhibition of TAK1, CLK2, GCK, ULK2, MAP4K5, IRAK1, NUAK, CSNK1G2, CAMKKβ-1, and MLK1, with IC50 values of 8.25, 29, 33, 63, 125, 264, 270, 810, 1280, and 5585 nM, respectively. HS-276 can be used for rheumatoid arthritis (RA) research. | ||
| M31005 | QTX125 TFA | HDAC |
| QTX125 TFA is a potent and highly selective HDAC6 inhibitor. QTX125 TFA exhibits excellent selectivity over other HDACs. QTX125 has antitumor effects. | ||
| M55679 | Recombinant Human CA125 Protein (HEK293, C-6His) | Cytokines and Growth Factors |
| FLJ14303; MUC16; mucin 16 | ||
| CA125 is a mucin protein that may be found in type I transmembrane or secreted forms that are used monitor the progress of epithelial ovarian cancer therapy. CA125 binds galectin-1 on immune cells and enhances its expression on tumor cells. CA125-expressing tumors adhere to NK cells, down-regulate CD16 and suppress NK response, which may promote immune evasion. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
